Characteristics of patients studied for pharmacokinetics and comparison with the demographics of patients in the RICOVER-60 trial
| Demographics . | Women . | Men . | All . |
|---|---|---|---|
| Median age, y (range) | 69 (61-79) | 69 (61-75) | 69 (61-79) |
| Median weight, kg (range) | 67 (43-85) | 82 (69-122) | 75 (43-122) |
| Median BSA, m2 (range) | 1.7 (1.5-1.9) | 2.0 (1.8-2.4) | 1.8 (1.5-2.4) |
| Sex, male/female, n (%) | 9 (45)/11 (55) | ||
| Ethnicity, white, n (%) | 20 (100) | ||
| Clinical data, n (range) | Women | Men | All |
| Alkaline phosphatase, U/L | 79 (50-130) | 70 (56-123) | 79.0 (50.0-133.0) |
| Bilirubin, mg/dL | 0.4 (0.2-1.0) | 0.5 (0.3-0.6) | 0.5 (0.2-1.0) |
| γ-glutamyl-transferase, U/L | 40 (20-201) | 39 (32-144) | 38.0 (19.0-201.0) |
| Creatinine, mg/dL | 0.7 (0.6-1.4) | 1.0 (0.7-1.2) | 1.0 (0.6-1.4) |
| Pharmacokinetic study | RICOVER-60 | ||
| Patients, N | 20 | 1222 | |
| LDH > UNV | 10 (50%) | 604 (49%) | |
| ECOG > 1 | 3 (15%) | 176 (14%) | |
| Stage | |||
| I | 4 (20%) | 268 (22%) | |
| II | 5 (25%) | 335 (27%) | |
| III | 2 (10%) | 316 (26%) | |
| IV | 9 (45%) | 303 (25%) | |
| Extranodal sites > 1 | 3 (15%) | 216 (18%) | |
| Bulky disease (> 7.5 cm) | 5 (25%) | 463 (38%) | |
| IPI score | |||
| 1 | 5 (25%) | 372 (30%) | |
| 2 | 7 (35%) | 339 (28%) | |
| 3 | 3 (15%) | 313 (26%) | |
| 4, 5 | 5 (25%) | 198 (16%) | |
| Demographics . | Women . | Men . | All . |
|---|---|---|---|
| Median age, y (range) | 69 (61-79) | 69 (61-75) | 69 (61-79) |
| Median weight, kg (range) | 67 (43-85) | 82 (69-122) | 75 (43-122) |
| Median BSA, m2 (range) | 1.7 (1.5-1.9) | 2.0 (1.8-2.4) | 1.8 (1.5-2.4) |
| Sex, male/female, n (%) | 9 (45)/11 (55) | ||
| Ethnicity, white, n (%) | 20 (100) | ||
| Clinical data, n (range) | Women | Men | All |
| Alkaline phosphatase, U/L | 79 (50-130) | 70 (56-123) | 79.0 (50.0-133.0) |
| Bilirubin, mg/dL | 0.4 (0.2-1.0) | 0.5 (0.3-0.6) | 0.5 (0.2-1.0) |
| γ-glutamyl-transferase, U/L | 40 (20-201) | 39 (32-144) | 38.0 (19.0-201.0) |
| Creatinine, mg/dL | 0.7 (0.6-1.4) | 1.0 (0.7-1.2) | 1.0 (0.6-1.4) |
| Pharmacokinetic study | RICOVER-60 | ||
| Patients, N | 20 | 1222 | |
| LDH > UNV | 10 (50%) | 604 (49%) | |
| ECOG > 1 | 3 (15%) | 176 (14%) | |
| Stage | |||
| I | 4 (20%) | 268 (22%) | |
| II | 5 (25%) | 335 (27%) | |
| III | 2 (10%) | 316 (26%) | |
| IV | 9 (45%) | 303 (25%) | |
| Extranodal sites > 1 | 3 (15%) | 216 (18%) | |
| Bulky disease (> 7.5 cm) | 5 (25%) | 463 (38%) | |
| IPI score | |||
| 1 | 5 (25%) | 372 (30%) | |
| 2 | 7 (35%) | 339 (28%) | |
| 3 | 3 (15%) | 313 (26%) | |
| 4, 5 | 5 (25%) | 198 (16%) | |
LDH indicates lactate dehydrogenase; UNV, upper normal value; and ECOG, Eastern Cooperative Oncology Group.